The text starts here.

Products

Our Products

At Eisai, we are currently undergoing a transformation from a two brand structure built upon the treatment for Alzheimer's disease Aricept® and the proton-pump inhibitor Pariet®/AcipHex® to a multi-brand structure established for the coordinated global launches for each of the four products of Halaven®, Lenvima®, Fycompa® and BELVIQ®, which form the basis of our next-generation product portfolio.

Oncology is one of the therapeutic areas in which we concentrate our efforts. Halaven®, a novel anticancer agent discovered and developed in-house, has been launched in Japan, the United States, Europe and Asia. Lenvima®, another anticancer agent discovered and developed in-house, has been launched in the United States, Japan and Europe in 2015. In addition, we currently market antiemetic agent Aloxi® in the United States and anticancer agent Treakisym®/Symbenda® as a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer in Singapore, South Korea and Japan.

Central nervous system diseases represent another key area of focus for Eisai. Aricept® was first launched in January 1997 in the United States and is now approved and marketed in more than 90 countries worldwide. Moreover, as a leading pharmaceutical company in the development of dementia treatments, we are also expanding our educational activities that promote the early diagnosis and early treatment of dementia. In Japan, Aricept was approved for the treatment of dementia with Lewy bodies in September 2014. In epilepsy, a relatively new area of therapeutic focus at Eisai, we provide multiple treatment options to cater to a diverse range of patient needs. These include Fycompa®, an AMPA receptor antagonist discovered in-house, Inovelon®/BANZEL®, a treatment for the rare disease of Lennox-Gastaut syndrome, and Zonegran® and Zebinix® as treatments for partial-onset seizures.

Another innovative neurology product we provide is BELVIQ®, which was launched in the United States in June 2013 as a treatment for obesity in adults. Furthermore, we have expanded the licensing agreement to market and distribute BELVIQ® in 21 countries throughout the Americas, to also include most countries and territories worldwide, most notably the European Union, Japan and China.

Meanwhile, as an advancement in the field of biologics represented by therapeutic antibodies, based on a licensing agreement with AbbVie GK, Eisai has launched Humira®, a fully human anti-TNF-α monoclonal antibody, as a treatment for immune-mediated diseases in Japan, South Korea and Taiwan. And in addition, in Japan we are focusing our efforts on promoting Lyrica®, a treatment for postherpetic neuralgia and Lunesta®, a treatment for insomnia.

(Information current as of June 2015)

Major Products

  Sales Regions
Oncology-Related Products
  Halaven (anticancer agent)
  Lenvima (anticancer agent)
  Aloxi (antiemetic agent)
  Treakisym/Symbenda (anticancer agent)
 
Japan, US, EUR, Asia
Japan, US, EUR
Americas
Japan, Asia
Epilepsy Products
  Fycompa (antiepileptic agent)
  Inovelon/BANZEL (antiepileptic agent)
  Zonegran (antiepileptic agent)
  Zebinix (antiepileptic agent)
 
Americas, EUR, Asia
Japan, US, EUR, Asia
EUR, Asia
EUR
Pariet/AcipHex (proton-pump inhibitor) Japan, US, EUR, China, Asia
Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies) Japan, US, EUR, China, Asia
Humira (fully human anti-TNF-α monoclonal antibody) Japan, South Korea, Taiwan

* Indication of Aricept for the treatment of dementia with Lewy bodies is approved only in Japan.

(Information current as of June 2015)

Major Products by Region

Japan Prescription Pharmaceuticals
Aricept (treatment for Alzheimer's disease / dementia with Lewy bodies)
Pariet (proton-pump inhibitor)
Humira (fully human anti-TNF-α monoclonal antibody)
Methycobal (peripheral neuropathy treatment)
Lyrica (pain treatment [neuropathic pain, fibromyalgia])
Warfarin (oral anticoagulant)
Actonel (osteoporosis treatment)
Halaven (anticancer agent)
Selbex (gastritis / gastric ulcer treatment)
Lunesta (insomnia treatment)
Consumer Healthcare (Over-the-Counter) Products
Chocola BB group (including Vitamin B2 preparation Chocola BB Plus)
Americas Aloxi (antiemetic agent)
Halaven (anticancer agent)
AcipHex (proton-pump inhibitor)
BANZEL (antiepileptic agent)
BELVIQ (antiobesity agent)
Fycompa (antiepileptic agent)
Lenvima (anticancer agent)
China Methycobal (peripheral neuropathy treatment)
Stronger Neo-Minophagen C / Glycyron tablets (liver disease / allergic disease treatment)
Aricept (treatment for Alzheimer's disease)
Pariet (proton-pump inhibitor)
Asia Aricept (treatment for Alzheimer's disease)
Humira (fully human anti-TNF-α monoclonal antibody)
Pariet (proton-pump inhibitor)
Methycobal (peripheral neuropathy treatment)
Halaven (anticancer agent)
Europe Halaven (anticancer agent)
Zonegran (antiepileptic agent)
Zebinix (antiepileptic agent)
Fycompa (antiepileptic agent)
Inovelon (antiepileptic agent)

(Information current as of June 2015)

Related Links